Evaluation of the microbiota-sparing properties of the anti-staphylococcal antibiotic afabicin.

ABSTRACT:

Background

Antibiotic use is associated with collateral damage to the healthy microbiota. Afabicin is a first-in-class prodrug inhibitor of the FabI enzyme that, when converted to the pharmacologically active agent afabicin desphosphono, demonstrates a staphylococcal-specific spectrum of activity. An expected benefit of highly targeted antibiotics such as afabicin is microbiome preservation.

Objectives

To compare the effects of oral treatment with afabicin and standard-of-care antibiotics upon the murine gut microbiota, and to assess the effects of oral afabicin treatment on the human gut microbiota.

Methods

Gut microbiota effects of a 10 day oral course of afabicin treatment were monitored in mice and compared with clindamycin, linezolid and moxifloxacin at human-equ

SUBMITTER: Nowakowska J 

PROVIDER: S-EPMC10393889 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature